$PESI

Why is Perma-Fix Environmental stock slipping today?

Perma-Fix Environmental Services (PESI) fell 0.8% to $17.31 in after-hours after a Q2 2026 business update. The company pre-announced revenue of about $13M and a net loss of about $6M, citing delays in Hanford waste treatment, project starts, and higher costs. Treatment backlog rose to about $15.7M. Lock-up restrictions from a May equity offering run until mid-August.

Original reporting
Published Aug 12, 2026, 10:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$PESI
Bearish
medium confidence
Mentioned
$PESI
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$PESIBearishMed
01

Why it matters

Traders may focus on whether delayed waste receipts are temporary versus structural, and whether backlog conversion into revenue accelerates after project start delays.

02

Market read

PESI’s pre-announced loss and near-term share-supply overhang from lock-up restrictions are the immediate drivers, while backlog growth provides a counterweight.

03

What to watch

The lock-up expiry is an overhang, but the article does not quantify how much selling is expected; actual share supply/demand could be less severe than implied.

Relevance 7/10Novelty 6/10Timing: after-hours today, ahead of the lock-up expiry window opening around Aug 13, 2026

Background

The article frames PESI’s after-hours dip around a Q2 2026 business update call and a pre-announced quarterly loss, with operational delays tied to Hanford waste streams.

Company-level read

Ticker impact

$PESIBearishMedium confidence
Context

Perma-Fix pre-announced Q2 2026 revenue of about $13M and net loss of about $6M, citing delayed Hanford waste treatment and higher costs.

Expected impact

Choppy-to-lower trading risk persists into the lock-up expiry window, with backlog growth acting as a partial offset.

Evidence & confidence

The article’s newest concrete items are the Q2 pre-announced loss drivers and the 91-day lock-up restriction ending around Aug 13, both of which can affect sentiment and supply/demand for shares.

Market effects

Competitive read-through for waste treatment peers, as PESI’s top-line underperformance is contrasted with stronger growth at Clean Harbors and Casella.

Limited direct regional impact; story is driven by U.S. DOE/Hanford-related project timing.

Low, primarily a U.S. government-linked services and small-cap sentiment story.

Counterpoint

Backlog growth of about $15.7M (up ~29% QoQ) and additional DOE and commercial awards could support a valuation re-rating if treatment receipts normalize.

Key entities

  • Perma-Fix Environmental Services

    Subject of the article, with a Q2 2026 pre-announced revenue and net loss, backlog growth, and a lock-up expiry window approaching.

  • Hanford-related waste streams

    Operational driver cited for delayed treatment and project start delays affecting near-term revenue recognition.

  • DOE and commercial awards

    Backlog-supporting awards cited as increasing services backlog over the next twelve months.

Related articles

$PESILow

5 Revealing Analyst Questions From Perma

Perma-Fix (PESI) reported a 11.7% YoY sales decline in Q2, missing adjusted earnings expectations. CEO Mark Duff cited cost-revenue mismatches and lower-margin inventory shifts. Analysts questioned waste volumes, regulatory permits, and processing capacity. The stock fell to $17.41 post-earnings. Management highlighted future catalysts, including permit approvals and DOE contract execution.

$PESIMed

Fix (PESI) Stock Trades Down, Here Is Why

Perma-Fix (NASDAQ: PESI) shares fell about 7.5% after the company reported Q2 results. Revenue was $12.89M, down 11.7% YoY and in line with expectations. The adjusted loss widened to $0.32 vs $0.31 forecast, with adjusted EBITDA down 156% YoY to -$5.89M. Management cited delayed treatment processing and higher costs, plus insider lock-up expiry.

$PESIMedAI 8/10

Perma-Fix (PESI) Stock Trades Down, Here Is Why

Perma-Fix (PESI) shares fell about 7.5% after the company reported Q2 results. Revenue was $12.89M, down 11.7% YoY and meeting expectations. The adjusted loss widened to $0.32 vs $0.31 forecast, with adjusted EBITDA down 156% YoY to -$5.89M. Management cited delayed treatment processing and higher costs, plus insider lock-up expiry.

$PESIMed

Fix’s (NASDAQ:PESI) Q2 CY2026 Earnings Results: Revenue In Line With Expectations, Stock Rises

Perma-Fix (NASDAQ: PESI) reported Q2 CY2026 revenue of $12.89 million, down 11.7% year on year but in line with Wall Street expectations. GAAP EPS was a loss of $0.32 per share, slightly better than consensus. The company said its Perma-Fix Northwest facility began receiving Hanford-related waste streams, increasing treatment backlog to about $15.7 million, and started receiving DFLAW liquid effluent in early July. PESI shares rose 7.8% to $20.93 after results.

$PESIMed

PERMA FIX ENVIRONMENTAL SERVICES INC (PESI): Results of Operations and Financial Condition

PERMA FIX ENVIRONMENTAL SERVICES INC (PESI) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0000891532 0000891532 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.